Antibody therapeutics product data - The Antibody Society

The Antibody Society continuously collects data for approved antibody therapeutics and those in regulatory review in the European Union (EU) or United States (US). A searchable table of this data is below. Products that were granted approvals but subsequently withdrawn from the market are included in the table. Biosimilar products are excluded.

Format, Fc modification and cell expression system data were compiled by Drs. Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.

Please cite our data as follows:
The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US. (date accessed); www.antibodysociety.org/antibody-therapeutics-product-data

International Non-Proprietary Name	Brand Name	Target	Format	Specificity	Sequence source	Backbone	Light Chain	Conjugated / uncognugated	Linker	Payload	Payload Mechanism of Action	Fc Modifications	Reason for Fc Modifications	Therapeutic Area	Indication First Approved or Reviewed	First EU approval year	First US approval year	Expression system
Muromonab-CD3	Orthoclone Okt3	CD3	Full-length antibody	Monospecific	Murine	mIgG2a	kappa	Unconjugated				None	-	Immunology	Reversal of kidney transplant rejection	1986*	1986#	Murine hybridoma
Efalizumab	Raptiva	CD11a	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Psoriasis	2004#	2003#	Chinese hamster ovary (CHO) cells
Tositumomab-I131	Bexxar	CD20	Full-length antibody	Monospecific	Murine	mIgG2a	lambda	Radio-immunotherapeutic		Iodine-131	I-131 produces beta and gamma emissions	None	-	Oncology	Non-Hodgkin Lymphoma	NA	2003#	Murine hybridoma
Nebacumab	Centoxin	Endotoxin	Full-length antibody	Monospecific	Human	hIgM	kappa	Unconjugated				None	-	Infectious Diseases	Gram-negative sepsis	1991*#	NA	Heteromyeloma cell line A6(H4C5)
Edrecolomab	Panorex	EpCAM	Full-length antibody	Monospecific	Murine	mIgG2a	kappa	Unconjugated				None	-	Oncology	Colon cancer	1995*#	NA
Catumaxomab	Removab	EPCAM, CD3	Full-length antibody	Bispecific	Hybrid Rat/Mouse	mIgG2a/k and rIgG2b/λ Hybrid	kappa/lambda	Unconjugated				None	-	Oncology	Malignant ascites	2009#	NA	Rat-mouse hybrid-hybridoma cell line
Daclizumab	Zinbryta; Zenapax	CD25	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Multiple sclerosis#; prevention of kidney transplant rejection#	2016#; 1999#	2016#; 1997#	Murine myeloma non-secreting 0 (NS0) cells
Abciximab	Reopro	GPIIb/IIIa	Fab	Monospecific	Chimeric mouse/human	hIgG1 Fab	kappa	Unconjugated				Not applicable	-	Hematological Disorders	Prevention of blood clots in angioplasty	1995*	1994	Murine myeloma cells (Sp2/0)
Rituximab	MabThera, Rituxan	CD20	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Oncology	Non-Hodgkin lymphoma	1998	1997	Chinese hamster ovary (CHO) cells
Basiliximab	Simulect	IL-2R	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Immunology	Prevention of kidney transplant rejection	1998	1998	Murine myeloma non-secreting 0 (NS0) cells
Palivizumab	Synagis	RSV	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Infectious Diseases	Prevention of respiratory syncytial virus infection	1999	1998	Murine myeloma non-secreting 0 (NS0) cells
Infliximab	Remicade	TNF	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Immunology	Crohn disease	1999	1998	Murine myeloma cells (Sp2/0)
Trastuzumab	Herceptin	HER2	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Oncology	Breast cancer	2000	1998	Chinese hamster ovary (CHO) cells
Adalimumab	Humira	TNF	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Immunology	Rheumatoid arthritis	2003	2002	Chinese hamster ovary (CHO) cells
Ibritumomab tiuxetan	Zevalin	CD20	Full-length antibody	Monospecific	Murine	mIgG1	kappa	Radio-immunotherapeutic	chalating agent MX-DTPA	Yttrium-90	Y-90 produces beta emissions	None	-	Oncology	Non-Hodgkin lymphoma	2004	2002	Chinese hamster ovary (CHO) cells
Omalizumab	Xolair	IgE	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Asthma	2005	2003	Chinese hamster ovary (CHO) cells
Cetuximab	Erbitux	EGFR	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Oncology	Colorectal cancer	2004	2004	Murine myeloma cells (Sp2/0)
Bevacizumab	Avastin	VEGF	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Oncology	Colorectal cancer	2005	2004	Chinese hamster ovary (CHO) cells
Natalizumab	Tysabri	a4 integrin	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				None	-	Immunology	Multiple sclerosis	2006	2004	Murine myeloma non-secreting 0 (NS0) cells
Panitumumab	Vectibix	EGFR	Full-length antibody	Monospecific	Human	hIgG2	kappa	Unconjugated				None	-	Oncology	Colorectal cancer	2007	2006	Chinese hamster ovary (CHO) cells
Ranibizumab	Lucentis	VEGF	Fab	Monospecific	Humanized	hIgG1 Fab	kappa	Unconjugated				Not applicable	-	Opthamology	Macular degeneration	2007	2006	E. coli bacteria
Eculizumab	Soliris	C5	Full-length antibody	Monospecific	Humanized	hIgG2(CH1-hinge)/hIgG4(CH2-CH3)	kappa	Unconjugated				None	-	Hematological Disorders	Paroxysmal nocturnal hemoglobinuria	2007	2007	Murine myeloma non-secreting 0 (NS0) cells
Certolizumab pegol	Cimzia	TNF	PEGylated Fab	Monospecific	Humanized	hFab		PEGylated		PEG	extend half life	Not applicable	-	Immunology	Crohn disease	2009	2008	E. coli bacteria
Ustekinumab	Stelara	IL-12/23	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Immunology	Psoriasis	2009	2009	Murine myeloma cells (Sp2/0)
Canakinumab	Ilaris	IL-1β	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Genetic Diseases	Muckle-Wells syndrome	2009	2009	Murine myeloma cells (Sp2/0)
Golimumab	Simponi	TNF	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Immunology	Rheumatoid and psoriatic arthritis, ankylosing spondylitis	2009	2009	Murine myeloma cells (Sp2/0)
Ofatumumab	Arzerra	CD20	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Oncology	Chronic lymphocytic leukemia	2010#	2009	Murine myeloma non-secreting 0 (NS0) cells
Tocilizumab	RoActemra, Actemra	IL-6R	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Rheumatoid arthritis	2009	2010	Chinese hamster ovary (CHO) cells
Denosumab	Prolia	RANK-L	Full-length antibody	Monospecific	Human	hIgG2	kappa	Unconjugated				None	-	Musculoskeletal Disorders	Bone Loss	2010	2010	Chinese hamster ovary (CHO) cells
Belimumab	Benlysta	BLyS	Full-length antibody	Monospecific	Human	hIgG1	lambda	Unconjugated				None	-	Immunology	Systemic lupus erythematosus	2011	2011	Murine myeloma non-secreting 0 (NS0) cells
Ipilimumab	Yervoy	CTLA-4	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Oncology	Metastatic melanoma	2011	2011	Chinese hamster ovary (CHO) cells
Brentuximab vedotin	Adcetris	CD30	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	ADC	protease cleavable linker (Cathepsin cleavable valine-citrulline)	Monometyl auristan E (MMAE)	tubulin polimerization inhibitor	None	-	Oncology	Hodgkin lymphoma, systemic anaplastic large cell lymphoma	2012	2011	Chinese hamster ovary (CHO) cells
Pertuzumab	Perjeta	HER2	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Oncology	Breast Cancer	2013	2012	Chinese hamster ovary (CHO) cells
Ado-trastuzumab emtansine	Kadcyla	HER2	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	ADC	Non-cleavable thioether linker	DM1	tubulin polimerization inhibitor	None	-	Oncology	Breast cancer	2013	2012	Chinese hamster ovary (CHO) cells
Raxibacumab	(Pending)	B. anthrasis PA	Full-length antibody	Monospecific	Human	hIgG1	lambda	Unconjugated				None	-	Infectious Diseases	Anthrax infection	NA	2012	Murine myeloma non-secreting 0 (NS0) cells
Obinutuzumab	Gazyva, Gazyvaro	CD20	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				Low-fucose	Improve FcγRIIIa binding/Improve ADCC	Oncology	Chronic lymphocytic leukemia	2014	2013	Chinese hamster ovary (CHO) cells, Coexpression with GnT III and α-ManII in CHO cells (GlycoMAb Technology)
Siltuximab	Sylvant	IL-6	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Immunology	Castleman disease	2014	2014	Chinese hamster ovary (CHO) cells
Ramucirumab	Cyramza	VEGFR2	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Oncology	Gastric cancer	2014	2014	Murine myeloma non-secreting 0 (NS0) cells
Vedolizumab	Entyvio	α4β7 integrin	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				L235A, G237	Remove Fc effector functions	Immunology	Ulcerative colitis, Crohn disease	2014	2014	Chinese hamster ovary (CHO) cells
Nivolumab	Opdivo	PD1	Full-length antibody	Monospecific	Human	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Melanoma, non-small cell lung cancer	2015	2014	Chinese hamster ovary (CHO) cells
Pembrolizumab	Keytruda	PD1	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Melanoma	2015	2014	Chinese hamster ovary (CHO) cells
Blinatumomab	Blincyto	CD19, CD3	Tandem scFv	Bispecific	Murine	Tandem scFv	NA	Unconjugated				Not applicable	-	Oncology	Acute lymphoblastic leukemia	2015	2014	Chinese hamster ovary (CHO) cells
Alemtuzumab	Lemtrada; MabCampath, Campath-1H	CD52	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Oncology	Multiple sclerosis; chronic myeloid leukemia#	2013; 2001#	2014; 2001#	Chinese hamster ovary (CHO) cells
Evolocumab	Repatha	PCSK9	Full-length antibody	Monospecific	Human	hIgG2	lambda	Unconjugated				None	-	Other	High cholesterol	2015	2015	Chinese hamster ovary (CHO) cells
Idarucizumab	Praxbind	Dabigatran	Fab	Monospecific	Humanized	hIgG1 Fab	kappa	Unconjugated				Not applicable	-	Hematological Disorders	Reversal of dabigatran-induced anticoagulation	2015	2015	Chinese hamster ovary (CHO) cells
Necitumumab	Portrazza	EGFR	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Oncology	Non-small cell lung cancer	2015	2015	Murine myeloma non-secreting 0 (NS0) cells
Dinutuximab	Unituxin	GD2	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Oncology	Neuroblastoma	2017; 2015#	2015	Murine myeloma cells (Sp2/0)
Secukinumab	Cosentyx	IL-17a	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Immunology	Psoriasis	2015	2015	Chinese hamster ovary (CHO) cells
Mepolizumab	Nucala	IL-5	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Severe eosinophilic asthma	2015	2015	Chinese hamster ovary (CHO) cells
Alirocumab	Praluent	PCSK9	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Other	High cholesterol	2015	2015	Chinese hamster ovary (CHO) cells
Daratumumab	Darzalex	CD38	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Oncology	Multiple myeloma	2016	2015	Chinese hamster ovary (CHO) cells
Elotuzumab	Empliciti	SLAMF7	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Oncology	Multiple myeloma	2016	2015	Murine myeloma non-secreting 0 (NS0) cells
Ixekizumab	Taltz	IL-17a	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Immunology	Psoriasis	2016	2016	Chinese hamster ovary (CHO) cells
Reslizumab	Cinqaero, Cinqair	IL-5	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				None	-	Immunology	Asthma	2016	2016	Murine myeloma non-secreting 0 (NS0) cells
Olaratumab	Lartruvo	PDGFRα	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Oncology	Soft tissue sarcoma	2016#	2016	Murine myeloma non-secreting 0 (NS0) cells
Bezlotoxumab	Zinplava	Clostridium difficile enterotoxin B	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Infectious Diseases	Prevention of Clostridium difficile infection recurrence	2017	2016	Chinese hamster ovary (CHO) cells
Atezolizumab	Tecentriq	PD-L1	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				Aglycosylated (N297A)	Remove Fc effector functions	Oncology	Bladder cancer	2017	2016	Chinese hamster ovary (CHO) cells
Obiltoxaximab	Anthim	B. anthrasis PA	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Infectious Diseases	Prevention of inhalational anthrax	2020	2016	Murine GS-NS0 myeloma cells
Brodalumab	Siliq, LUMICEF, Kyntheum	IL-17R	Full-length antibody	Monospecific	Human	hIgG2	kappa	Unconjugated				None	-	Immunology	Plaque psoriasis	2017	2017	Chinese hamster ovary (CHO) cells
Dupilumab	Dupixent	IL-4R α	Full-length antibody	Monospecific	Human	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Immunology	Atopic dermatitis	2017	2017	Chinese hamster ovary (CHO) cells
Inotuzumab ozogamicin	BESPONSA	CD22	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	ADC	Acid-labile hydrozone linker	Calicheamicin	DNA-binding and double breaks induction	S228P	Hinge stabilising	Oncology	Acute lymphoblastic leukemia	2017	2017	Chinese hamster ovary (CHO) cells
Guselkumab	TREMFYA	IL-23 p19	Full-length antibody	Monospecific	Human	hIgG1	lambda	Unconjugated				None	-	Immunology	Plaque psoriasis	2017	2017	Chinese hamster ovary (CHO) cells
Sarilumab	Kevzara	IL-6R	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Immunology	Rheumatoid arthritis	2017	2017	Chinese hamster ovary (CHO) cells
Avelumab	Bavencio	PD-L1	Full-length antibody	Monospecific	Human	hIgG1	lambda	Unconjugated				None	-	Oncology	Merkel cell carcinoma	2017	2017	Chinese hamster ovary (CHO) cells
Emicizumab	Hemlibra	Factor Ixa, X	Full-length antibody	Bispecific	Humanized	hIgG4	kappa	Unconjugated				S228P; K196Q; F296Y; E356K; K439E; L445P; G446 > del; K447 > del	Hinge stabilising, asymmetric electrostatic steering mutations for bispecific creation	Hematological Disorders	Hemophilia A	2018	2017	Chinese hamster ovary (CHO) cells
Ocrelizumab	OCREVUS	CD20	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Multiple sclerosis	2018	2017	Chinese hamster ovary (CHO) cells
Benralizumab	Fasenra	IL-5R α	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				Afucosylated	Improve FcγRIIIa binding/Improve ADCC	Immunology	Asthma	2018	2017	Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
Durvalumab	IMFINZI	PD-L1	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				L234F; L235E; P331S	Remove Fc effector functions	Oncology	Bladder cancer	2018	2017	Chinese hamster ovary (CHO) cells
Gemtuzumab ozogamicin	Mylotarg	CD33	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	ADC	Acid-labile hydrozone linker	Calicheamicin	DNA-binding and double breaks induction	S228P	Hinge stabilising	Oncology	Acute myeloid leukemia	2018	2017; 2000#	Murine myeloma non-secreting 0 (NS0) cells
Erenumab (erenumab-aooe)	Aimovig	CGRP receptor	Full-length antibody	Monospecific	Human	hIgG2	lambda	Unconjugated				None	-	Neurological disorders	Migraine prevention	2018	2018	Chinese hamster ovary (CHO) cells
Galcanezumab (galcanezumab-gnlm)	Emgality	CGRP	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P; F234A; L235A	Remove Fc effector functions	Neurological disorders	Migraine prevention	2018	2018	Chinese hamster ovary (CHO) cells
Burosumab (burosumab-twza)	Crysvita	FGF23	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Genetic Diseases	X-linked hypophosphatemia	2018	2018	Chinese hamster ovary (CHO) cells
Lanadelumab (lanadelumab-flyo)	Takhzyro	Plasma kallikrelin	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Genetic Diseases	Hereditary angioedema attacks	2018	2018	Chinese hamster ovary (CHO) cells
Mogamulizumab (mogamulizumab-kpkc)	Poteligeo	CCR4	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				Afucosylated	Improve FcγRIIIa binding/Improve ADCC	Oncology	Mycosis fungoides or Sézary syndrome	2018	2018	Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
Tildrakizumab (tildrakizumab-asmn)	Ilumya	IL-23 p19	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Plaque psoriasis	2018	2018	Chinese hamster ovary (CHO) cells
Fremanezumab (fremanezumab-vfrm)	Ajovy	CGRP	Full-length antibody	Monospecific	Humanized	hIgG2Δa	kappa	Unconjugated				A330S; P331S	Remove Fc effector functions	Neurological disorders	Migraine prevention	2019	2018	Chinese hamster ovary (CHO) cells
Ravulizumab (ravulizumab-cwvz)	Ultomiris	C5	Full-length antibody	Monospecific	Humanized	hIgG2(CH1-hinge)/hIgG4(CH2-CH3)	kappa	Unconjugated				M428L; N434S	Increase half-life	Hematological Disorders	Paroxysmal nocturnal hemoglobinuria	2019	2018	Chinese hamster ovary (CHO) cells
Cemiplimab (cemiplimab-rwlc)	Libtayo	PD-1	Full-length antibody	Monospecific	Human	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Cutaneous squamous cell carcinoma	2019	2018	Chinese hamster ovary (CHO) cells
Ibalizumab (ibalizumab-uiyk)	Trogarzo	CD4	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				None	-	Infectious Diseases	HIV infection	2019	2018	Murine myeloma non-secreting 0 (NS0) cells
Emapalumab (emapalumab-lzsg)	Gamifant	IFNg	Full-length antibody	Monospecific	Human	hIgG1	lambda	Unconjugated				None	-	Oncology	Primary hemophagocytic lymphohistiocytosis	NA	2018	Chinese hamster ovary (CHO) cells
Moxetumomab pasudotox (moxetumomab pasudotox-tdfk)	Lumoxiti	CD22	dsFv immunotoxin	Monospecific	Murine	mIgG1 dsFv fused with PE38 exotoxin		Immunotoxin		PE38		Not applicable	-	Oncology	Hairy cell leukemia	2021	2018	E. coli bacteria
Caplacizumab (caplacizumab-yhdp)	Cablivi	von Willebrand factor	Nanobody	Monospecific	Humanized	bivalent Nanobody	NA	Unconjugated				Not applicable	-	Immunology	Acquired thrombotic thrombocytopenic purpura	2018	2019	E. coli bacteria
Risankizumab (risankizumab-rzaa)	Skyrizi	IL-23 p19	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				L234A; L235A	Remove Fc effector functions	Immunology	Plaque psoriasis	2019	2019	Chinese hamster ovary (CHO) cells
Polatuzumab vedotin (polatuzumab vedotin-piiq)	Polivy	CD79b	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	ADC	Protease-cleavable linker	Monomethyl Auristatin E (MMAE)	tubulin polimerization inhibitor	None	-	Oncology	Diffuse large B-cell lymphoma	2020	2019	Chinese hamster ovary (CHO) cells
Romosozumab (romosozumab-aqqg)	Evenity	Sclerostin	Full-length antibody	Monospecific	Humanized	hIgG2	kappa	Unconjugated				None	-	Musculoskeletal Disorders	Osteoporosis in postmenopausal women at increased risk of fracture	2019	2019	Chinese hamster ovary (CHO) cells
Brolucizumab (brolucizumab-dbll)	Beovu	VEGF-A	scFv	Monospecific	Humanized	hscFv	kappa	Unconjugated				Not applicable	-	Opthamology	Neovascular age-related macular degeneration	2020	2019	E. coli BL21(DE3) bacteria
Crizanlizumab (crizanlizumab-tmca)	Adakveo	CD62 (aka P-selectin)	Full-length antibody	Monospecific	Humanized	hIgG2	kappa	Unconjugated				None	-	Hematological Disorders	Sickle cell disease	2020	2019	Chinese hamster ovary (CHO) cells
Enfortumab vedotin (enfortumab vedotin-ejfv)	Padcev	Nectin-4	Full-length antibody	Monospecific	Human	hIgG1	kappa	ADC	Protease-cleavable linker	Monomethyl Auristatin E (MMAE)	tubulin polimerization inhibitor	None	-	Oncology	Urothelial cancer	EU review (Pos opinion)	2019	Chinese hamster ovary (CHO) cells
[fam-]trastuzumab deruxtecan, (fam-trastuzumab deruxtecan-nxki)	Enhertu	HER2	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	ADC	Protease-cleavable linker	DXd	topoisomerase I inhibitor	None	-	Oncology	HER2+ metastatic breast cancer	2021	2019	Chinese hamster ovary (CHO) cells
Teprotumumab (teprotumumab-trbw)	Tepezza	IGF-1R	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Opthamology	Thyroid eye disease	NA	2020	Chinese hamster ovary (CHO) cells
Eptinezumab (eptinezumab-jjmr)	VYEPTI	CGRP	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				Aglycosylated (N297A)	Remove Fc effector functions	Neurological disorders	Migraine prevention	EU review (Pos opinion)	2020	Pichia pastoris yeast cells
Isatuximab (isatuximab-irfc)	Sarclisa	CD38	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				None	-	Oncology	Multiple myeloma	2020	2020	Chinese hamster ovary (CHO) cells
Sacituzumab govitecan (sacituzumab govitecan-hziy)	TRODELVY	TROP-2	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	ADC	pH-sensitive cleavable linker	SN38	topoisomerase I inhibitor	None	-	Oncology	Triple-neg. breast cancer	2021	2020	Murine myeloma cells
Inebilizumab (inebilizumab-cdon)	Uplizna	CD19	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				Afucosylated	Improve FcγRIIIa binding/Improve ADCC	Immunology	Neuromyelitis optica spectrum disorders	EU review (Pos opinion)	2020	Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
Tafasitamab (tafasitamab-cxix)	Monjuvi, Minjuvi	CD19	Full-length antibody	Monospecific	Humanized	hIgG1/2 hybrid	kappa	Unconjugated				S239D; I332E	Improve FcγRIIIa binding/Improve ADCC	Oncology	Diffuse large B-cell lymphoma	2021	2020	Chinese hamster ovary (CHO) cells
Belantamab mafodotin (belantamab mafodotin-blmf)	BLENREP	B-cell maturation antigen	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	ADC	noncleavable maleimidocaproyl (mc) linker	Monomethyl Auristatin F (MMAF)	tubulin polimerization inhibitor	Afucosylated	Improve FcγRIIIa binding/Improve ADCC	Oncology	Multiple myeloma	2020	2020	Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
Satralizumab (satralizumab-mwge)	Enspryng	IL-6R	Full-length antibody	Monospecific	Humanized	hIgG2	kappa	Unconjugated				None	-	Immunology	Neuromyelitis optica spectrum disorder	2021	2020	Chinese hamster ovary (CHO) cells
Atoltivimab, maftivimab, and odesivimab-ebgn	Inmazeb	Ebola virus	Full-length antibodies, mixture of 3	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Infectious Diseases	Ebola virus infection	NA	2020	Chinese hamster ovary (CHO) cells
Naxitamab-gqgk	DANYELZA	GD2	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Oncology	High-risk neuroblastoma and refractory osteomedullary disease	NA	2020	Chinese hamster ovary (CHO) cells
Margetuximab-cmkb	MARGENZA	HER2	Full-length antibody	Monospecific	Chimeric mouse/human	hIgG1	kappa	Unconjugated				F243L; R292P; Y300L; V305I; P396L	Improve FcγRIIIa binding/Improve ADCC and decrease affinity for human inhibitory FcγRIIB (CD32B)	Oncology	HER2+ metastatic breast cancer	NA	2020	Chinese hamster ovary (CHO) cells
Ansuvimab-zykl	Ebanga	Ebola virus glycoprotein	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Infectious Diseases	Ebola virus infection	NA	2020	Chinese hamster ovary (CHO) cells
Evinacumab	Evkeeza	Angiopoietin-like 3	Full-length antibody	Monospecific	Human	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Genetic Diseases	Homozygous familial hypercholesterolemia	2021	2021	Chinese hamster ovary (CHO) cells
Loncastuximab tesirine	Zynlonta	CD19	Full-length antibody	Monospecific	Humanized	hIgG1/k	kappa	ADC	Protease-cleavable linker	pyrrolobenzodiazepines (PBD) dimer SG3199	DNA minor-groove binding	None	-	Oncology	Diffuse large B-cell lymphoma	EU review	2021	Chinese hamster ovary (CHO) cells
Dostarlimab	Jemerli	PD-1	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Endometrial cancer	2021	2021	Chinese hamster ovary (CHO) cells
Amivantamab	RYBREVANT	EGFR, cMET	Full-length antibody	Bispecific	Human	hIgG1		Unconjugated				Low-fucose; K409R; F405L	Improve FcγRIIIa binding/Improve ADCC; Controlled Fab arm exchange for bispecific generation	Oncology	NSCLC w/ EGFR exon 20 insertion mutations	2021	2021	Chinese hamster ovary (CHO) cells, Low-fucose production cells
Aducanumab	ADUHELM	Amyloid beta	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				None	-	Neurological disorders	Alzheimer's disease	Neg opinion	2021	Chinese hamster ovary (CHO) cells
Tralokinumab	Adtralza	IL-13	Full-length antibody	Monospecific	Human	hIgG4	lambda	Unconjugated				None	-	Immunology	Atopic dermatitis	2021	2021	Mouse myeloma cells
Teplizumab	(Pending)	CD3	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				L234A; L235A	Remove Fc effector functions	Immunology	Type 1 diabetes	NA	In review (2nd cycle)	To be confirmed
Narsoplimab	(Pending)	MASP-2	Full-length antibody	Monospecific	Human	hIgG4	lambda	Unconjugated				S228P	Hinge stabilising	Hematological Disorders	Hematopoietic stem cell transplant-associated thrombotic microangiopathies	NA	In review	To be confirmed
Retifanlimab	(Pending)	PD-1	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Carcinoma of the anal canal	MAA withdrawn	In review (2nd cycle)	To be confirmed
Oportuzumab monatox	(Pending)	EpCAM	scFv immunotoxin	Monospecific	Humanized	hscFv fused with PE38 exotoxin	To be confirmed	Immunotoxin		PE38		Not applicable	-	Oncology	Bladder cancer	NA	In review (2nd cycle)	To be confirmed
Anifrolumab, anifrolumab-fnia	Saphnelo	IFNAR1	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated				L234F; L235E; P331S	Remove Fc effector functions	Immunology	Systemic lupus erythematosus	EU review (Pos opinion)	2021	Mouse myeloma cells (NS0)
Inolimomb	(Pending)	CD25	Full-length antibody	Monospecific	Murine	mIgG1	kappa	Unconjugated				None	-	Immunology	Graft vs. host disease	NA	In review	To be confirmed
Bimekizumab	Bimzelx	IL-17A and IL-17F (overlapping binding site)	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				None	-	Immunology	Psoriasis	2021	In review	Chinese hamster ovary (CHO) cells
Sutimlimab	(Pending)	C1s	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P; L235E	Hinge stabilising; remove Fc effector functions	Immunology	Cold agglutinin disease	EU review	In review (2nd cycle)	To be confirmed
Ublituximab	(Pending)	CD20	Full-length antibody	Monospecific	Chimeric	hIgG1	kappa	Unconjugated				Low fucose	Improve FcγRIIIa binding/Improve ADCC	Oncology	Chronic lymphocytic leukemia	EU review	In review	YB2/0 cells
Tisotumab vedotin, tisotumab vedotin-tftv	TIVDAK	Tissue factor	Full-length antibody	Monospecific	Human	hIgG1	kappa	ADC	Cleavable mc-val-cit-PABC type linker	Monomethyl Auristatin E (MMAE)	tubulin polimerization inhibitor	None	-	Oncology	Cervical cancer	NA	2021	Chinese hamster ovary (CHO) cells
Toripalimab	Tuoyi	PD-1	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Nasopharyngeal carcinoma	NA	In review	To be confirmed
Sintilimab	Tyvyt	PD-1	Full-length antibody	Monospecific	Human	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Non-small cell lung cancer	NA	In review	To be confirmed
Tezepelumab	Tezspire	Thymic stromal lymphopoietin	Full-length antibody	Monospecific	Human	hIgG2	lambda	Unconjugated				To be confirmed		Immunology	Severe asthma	EU review	2021	Chinese hamster ovary (CHO) cells
Omburtamab	(Pending)	B7-H3 (CD276)	Full-length antibody	Monospecific	Murine	hIgG1	kappa	Radiolabeled		Iodine-131	I-131 produces beta and gamma emissions	To be confirmed		Oncology	Central nervous system/leptomeningeal metastasis from neuroblastoma	EU review	NA	To be confirmed
Penpulimab	(Pending)	PD-1	Full-length antibody	Monospecific	Humanized	hIgG1	To be confirmed	Unconjugated				To be confirmed		Oncology	Metastatic nasopharyngeal carcinoma	NA	In review	To be confirmed
Faricimab	(Pending)	VEGF-A, Ang-2	Full-length antibody	Bispecific	Humanized/human	hIgG1	kappa/lambda	Unconjugated				L234A; L235A; P329G; I253A; H310A; H435A; S354C + T366W (in heavy chain A); Y349C + T366S + L368A + Y407V (in heavy chain B)	Remove Fc effector functions; Reduce half-life; CrossMab "knob-in-hole" mutations for bispecific generation	Ophthamology	Neovascular age-related macular degeneration, diabetic macular edema	EU review	In review	Chinese hamster ovary (CHO) cells
Tebentafusp	(Pending)	gp100, CD3	TCR-scFv fusion protein	Bispecific	Humanized	hscFV fused with a TCR	To be confirmed	Fusion protein						Oncology	Metastatic uveal melanoma	EU review	In review	To be confirmed
Tislelizumab	(Pending)	PD-1	Full-length antibody	Monospecific	Humanized	hIgG4	kappa	Unconjugated				S228P; E233P, F234V, L235A, D265A	Hinge stabilising; Abrogate FcγRs binding	Oncology	Esophageal squamous cell carcinoma	NA	In review	To be confirmed
Relatlimab	(Pending)	LAG-3	Full-length antibody	Monospecific	Human	hIgG4	kappa	Unconjugated				S228P	Hinge stabilising	Oncology	Melanoma	EU review	In review	To be confirmed
Lecanemab	(Pending)	Amyloid beta protofibrils	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated						Neurological disorders	Alzheimer's disease	NA	In review	To be confirmed
Casirivimab + imdevimab	REGEN-COV, Ronapreve	SARS-CoV-2	Full-length antibodies, mixture of 2	Monospecific	Human	hIgG1	kappa and lambda	Unconjugated						Infectious diseases	COVID-19	2021	In review	Chinese hamster ovary (CHO) cells
Regdanvimab	Regkirona	SARS-CoV-2	Full-length antibody	Monospecific	Human	hIgG1	lambda	Unconjugated						Infectious diseases	COVID-19	2021	NA	Chinese hamster ovary (CHO)-K1 cells
Spesolimab	(Pending)	IL-36 receptor	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated				L234A/L235A	Remove Fc effector functions	Immune-mediated disorders	Generalized pustular psoriasis	EU review	In review	To be confirmed
Donanemab	(Pending)	Amyloid beta, N3pG (N-terminal truncated)	Full-length antibody	Monospecific	Humanized	hIgG1	kappa	Unconjugated						Neurological disorders	Alzheimer's disease	NA	In review	To be confirmed
Sotrovimab	Xevudy	SARS-CoV-2	Full-length antibody	Monospecific	Human	hIgG1	kappa	Unconjugated						Infectious diseases	COVID-19	2021	NA	Chinese hamster ovary (CHO) cells
Teclistamab	(Pending)	BCMA, CD3	Full-length antibody	Bispecific	Humanized	IgG4; Hetero H, HL exchanged	lambda	Unconjugated				Hetero HH: F405L-R409K x WT (R409); both chains: S228P and F234A, L235A	Hinge-stabilising (S228P) and Fc-silencing (F234A, L235A)	Oncology	Multiple myeloma	NA	In review	To be confirmed
Mosunetuzumab	(Pending)	CD20, CD3	Full-length antibody	Bispecific	Humanized	IgG1; Hetero H, HL assembly	kappa	Unconjugated				Hetero HH: T366W x T366S-L368A-Y407V (KiH); N297G (Fc-aglycosylated)	Improve FcγRIIIa binding/Improve ADCC	Oncology	Follicular lymphoma	EU review	NA	To be confirmed
Tremelimumab	(Pending)	CTLA-4	Full-length antibody	Monospecific	Human	IgG2	kappa	Unconjugated						Oncology	Non-small cell lung cancer	EU review	NA	To be confirmed

Table notes: *, Country-specific approval. #, Withdrawn or marketing discontinued. NA, not approved or in review in the EU; not approved or information on review status not available in US.

Sequence and structure information can be accessed on the IMGT/mAb-DB website.

Antibody therapeutics that are approved for marketing in regions other than the EU or US include:
Nimotuzumab (TheraCIM®, BIOMAB-EGFR®), humanized anti-EGFR IgG1 approved in numerous countries for various forms of solid tumors starting in the 2000s.

Itolizumab (Alzumab), humanized anti-CD6 IgG1 approved in India in January 2013 for psoriasis;
Rmab (RabiShield), human anti-rabies virus G glycoprotein IgG1 approved in India in 2016 for post-exposure prophylaxis of rabies;
RabiMabs (Twinrab TM), mixture of 2 anti-rabies virus mAbs approved in India in 2019.

Sintilimab (Tyvyt), human IgG4 anti-PD-1 mAb approved in China in December 2018 for Hodgkin’s lymphoma;
Toripalimab (Tuoyi), humanized anti-PD-1 mAb approved in China in December 2018 for melanoma;
Camrelizumab, humanized anti-PD-1 mAb approved in China in 2019 for Hodgkin’s lymphoma;
Tislelizumab, humanized anti-PD-1 mAb, approved in China in December 2019 as a treatment for classical Hodgkin’s lymphoma;
Disitamab vedotin (Aidixi), anti-HER2 humanized ADC approved in China in June 2021 as a treatment for gastric cancer;
Penpulimab, ant-PD-1 humanized mAb approved in China in August 2021 for Hodgkin’s lymphoma;
Zimberelimab, anti-PD-1 human mAb approved in China in August 2021 for Hodgkin’s lymphoma.

Netakimab (Efleira), anti-IL-17 mAb approved in Russia in 2019 for plaque psoriasis;
Prolgolimab (Forteca), anti-PD-1 mAb approved in Russia in 2020 for melanoma;
Olokizumab (Artlegia), anti-IL-6 humanized IgG4 approved in Russia in 2020 for rheumatoid arthritis;
Levilimab (Ilsira) anti-IL-6R human mAb approved in Russia in 2020 for COVID-19.

Cetuximab saratolacan sodium, anti-EGFR mAb approved in Japan in September 2020 for head and neck cancer;
Pabinafusp alfa (IZCARO), anti-transferrin receptor inmmunoconjuate approve in Japan in March 2021 for Hunter syndrome.

Sotrovimab, anti-SARS-CoV-2 antibody approved in Australia in August 2021.
Regdanvimab, anti-SARS-CoV-2 antibody approved in the Republic of Korea in September 2021.

Please cite our data as follows: The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US. (date accessed); www.antibodysociety.org/antibody-therapeutics-product-data

Please cite our data as follows:
The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US. (date accessed); www.antibodysociety.org/antibody-therapeutics-product-data